231,375 Shares in Organon & Co. (NYSE:OGN) Bought by Prevail Innovative Wealth Advisors LLC

Prevail Innovative Wealth Advisors LLC acquired a new position in Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 231,375 shares of the company's stock, valued at approximately $3,336,000. Organon & Co. comprises approximately 1.6% of Prevail Innovative Wealth Advisors LLC's holdings, making the stock its 12th largest position. Prevail Innovative Wealth Advisors LLC owned 0.09% of Organon & Co. at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC grew its holdings in Organon & Co. by 348.3% during the fourth quarter. Lindbrook Capital LLC now owns 1,838 shares of the company's stock valued at $27,000 after purchasing an additional 1,428 shares during the last quarter. Headlands Technologies LLC acquired a new position in Organon & Co. during the third quarter valued at approximately $35,000. Gladius Capital Management LP boosted its position in shares of Organon & Co. by 65.1% in the fourth quarter. Gladius Capital Management LP now owns 2,176 shares of the company's stock valued at $31,000 after acquiring an additional 858 shares during the period. Clear Street Markets LLC boosted its position in shares of Organon & Co. by 588.9% in the third quarter. Clear Street Markets LLC now owns 2,294 shares of the company's stock valued at $40,000 after acquiring an additional 1,961 shares during the period. Finally, GAMMA Investing LLC bought a new stake in shares of Organon & Co. in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 77.43% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on OGN shares. Piper Sandler increased their price objective on Organon & Co. from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Monday, April 29th. The Goldman Sachs Group increased their price objective on Organon & Co. from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Friday, May 3rd.

Organon & Co. Stock Performance

OGN stock traded up $0.06 during midday trading on Monday, hitting $21.39. The stock had a trading volume of 1,290,382 shares, compared to its average volume of 2,550,439. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of 5.23, a P/E/G ratio of 0.93 and a beta of 0.86. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $24.08. The stock has a 50-day simple moving average of $19.51 and a 200 day simple moving average of $16.88. The company has a current ratio of 1.65, a quick ratio of 1.15 and a debt-to-equity ratio of 181.35.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, May 2nd. The company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.83 by $0.31. The firm had revenue of $1.62 billion during the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. As a group, equities research analysts anticipate that Organon & Co. will post 4.3 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be given a $0.28 dividend. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 annualized dividend and a yield of 5.24%. Organon & Co.'s dividend payout ratio (DPR) is currently 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.